Menu Search
Equities

Uniqure NV

QUREN:MEX

Uniqure NV

Actions
  • Price (MXN)118.63
  • Today's Change43.89 / 58.72%
  • Shares traded100.00
  • 1 Year change-67.38%
  • Beta--
Data delayed at least 20 minutes, as of Nov 27 2023 11:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

  • Revenue in USD (TTM)15.84m
  • Net income in USD-308.48m
  • Incorporated2012
  • Employees480.00
  • Location
    Uniqure NVPaasheuvelweg 25aAMSTERDAM 1105 BPNetherlandsNLD
  • Phone+31 202406000
  • Fax+31 202406020
  • Websitehttp://www.uniqure.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.